Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

ANDA Submissions Continue Yo-Yo Pattern, Unlike Approvals

May 10 2017

• By Derrick Gingery

StacksOfPapers_1200x675

Related Content

Generic Drug Puzzle: Why Did ANDA Submissions Spike Again?

Apr 11 2017

FDA Guides ANDA Sponsors On Being “Easily Correctable”

Jul 21 2014

ANDA Stress Test: End-Of-Year Submission Bolus Pressures US FDA Review System

Jan 09 2017

ANDA Reviews: First-Cycle Desired, But Two-Cycles OK?

Jul 27 2015

FDA Hiring Campaign Continues; Goal Is Addressing Pending ANDAs

Sep 27 2016

Generic Drug First-Cycle Approval Rates Lagging Under GDUFA I

Oct 26 2016

ANDA Approval Improvements Reveal Just How Big The Backlog Is

Oct 12 2015

ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal

Sep 24 2016

Another ANDA Submission Surge Begins

Nov 22 2016

Additional Topics

United States FDA Generic Drugs Regulation Approvals BioPharmaceutical

More from Generics

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window